The 10 most recent market catalysts affecting $TENX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Bearish
Impact 75
Tenax Therapeutics shares are trading lower after Guggenheim downgraded the stock from Buy to Neutral rating.
This downgrade is a significant corporate catalyst for Tenax Therapeutics. Analyst downgrades, especially from prominent firms like Guggenheim, often trigger immediate negative pri…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 65
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Chardan Capital analyst Gautam Chukka downgraded Tenax Therapeutics (TENX) from a 'Buy' rating to 'Neutral' and drastically cut the price target from $27 to $5. This move signals a…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 65
Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Evercore ISI Group analyst Gavin Clark-Gartner downgraded Tenax Therapeutics (TENX) from 'Outperform' to 'In-Line' and drastically cut the price target from $39 to $5. This move si…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics reported disappointing topline results from its Phase 3 LEVEL study for TNX-103, failing to meet its primary endpoint for exercise capacity improvement and a key…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
Tenax Therapeutics shares are trading lower after the company announced its Phase 3 LEVEL clinical trial evaluating TNX-103 did not meet its primary or key secondary endpoints.
The failure of a Phase 3 clinical trial is a catastrophic event for a biotechnology company, especially when it involves a lead drug candidate like TNX-103. This outcome directly i…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 65
Tenax Therapeutics Q2 EPS $(0.35) Beats $(0.37) Estimate
Tenax Therapeutics announced its Q2 earnings, reporting a loss of $(0.35) per share. While this figure beat the consensus analyst estimate of $(0.37), it's crucial to note that the…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
Canaccord Genuity Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $35
Canaccord Genuity has initiated coverage on Tenax Therapeutics (TENX) with a 'Buy' rating and a substantial price target of $35. This event is significant because new analyst cover…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 65
Evercore ISI Group Initiates Coverage On Tenax Therapeutics with Outperform Rating, Announces Price Target of $39
Evercore ISI Group's analyst Gavin Clark-Gartner has initiated coverage on Tenax Therapeutics (TENX) with an 'Outperform' rating and a price target of $39. This event is significan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.